NanoViricides, Inc. (NNVC)
USD 1.5
(0.67%)
USD 1.5
(0.67%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 | -0.70 USD | 5.41% |
| 2023 | -0.74 USD | -5.71% |
| 2022 | -0.70 USD | 14.63% |
| 2021 | -0.82 USD | 65.69% |
| 2020 | -2.39 USD | -3.91% |
| 2019 | -2.30 USD | 12.88% |
| 2018 | -2.64 USD | 23.03% |
| 2017 | -3.43 USD | 7.8% |
| 2016 | -3.72 USD | -376.92% |
| 2015 | -0.78 USD | 85.84% |
| 2014 | -5.51 USD | -42.38% |
| 2013 | -3.87 USD | -33.45% |
| 2012 | -2.90 USD | 11.04% |
| 2011 | -3.26 USD | -28.35% |
| 2010 | -2.54 USD | -55.83% |
| 2009 | -1.63 USD | 0.61% |
| 2008 | -1.64 USD | 15.46% |
| 2007 | -1.94 USD | 12.61% |
| 2006 | -2.22 USD | -4705.19% |
| 2005 | -0.05 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.17 USD | 45.16% |
| 2024 Q4 | -0.20 USD | -25.0% |
| 2024 Q3 | -0.16 USD | 11.11% |
| 2024 Q2 | -0.18 USD | -5.88% |
| 2023 Q3 | -0.14 USD | 0.0% |
| 2023 Q4 | -0.31 USD | -121.43% |
| 2023 Q2 | -0.14 USD | -7.69% |
| 2023 Q1 | -0.13 USD | 13.33% |
| 2023 FY | - USD | -5.71% |
| 2022 Q1 | -0.23 USD | -21.05% |
| 2022 FY | - USD | 14.63% |
| 2022 Q4 | -0.15 USD | 6.25% |
| 2022 Q2 | -0.17 USD | 26.09% |
| 2022 Q3 | -0.16 USD | 5.88% |
| 2021 Q2 | -0.22 USD | 0.0% |
| 2021 Q3 | -0.19 USD | 13.64% |
| 2021 Q1 | -0.22 USD | -22.22% |
| 2021 Q4 | -0.19 USD | 0.0% |
| 2021 FY | - USD | 65.69% |
| 2020 Q4 | -0.18 USD | 85.48% |
| 2020 FY | - USD | -3.91% |
| 2020 Q1 | -0.41 USD | 29.31% |
| 2020 Q2 | -0.50 USD | -21.95% |
| 2020 Q3 | -1.24 USD | -148.0% |
| 2019 Q2 | -0.64 USD | -20.75% |
| 2019 Q3 | -0.59 USD | 7.81% |
| 2019 FY | - USD | 12.88% |
| 2019 Q4 | -0.58 USD | 1.69% |
| 2019 Q1 | -0.53 USD | -10.42% |
| 2018 FY | - USD | 23.03% |
| 2018 Q4 | -0.48 USD | 27.27% |
| 2018 Q3 | -0.66 USD | 25.0% |
| 2018 Q2 | -0.88 USD | -39.68% |
| 2018 Q1 | -0.63 USD | 22.22% |
| 2017 Q4 | -0.81 USD | 21.36% |
| 2017 FY | - USD | 7.8% |
| 2017 Q1 | -1.05 USD | -84.21% |
| 2017 Q2 | -0.53 USD | 49.52% |
| 2017 Q3 | -1.03 USD | -94.34% |
| 2016 Q3 | -1.73 USD | -80.21% |
| 2016 Q2 | -0.96 USD | -108.7% |
| 2016 FY | - USD | -376.92% |
| 2016 Q4 | -0.57 USD | 67.05% |
| 2016 Q1 | -0.46 USD | -43.75% |
| 2015 Q4 | -0.32 USD | -262.81% |
| 2015 Q2 | -0.67 USD | -679.07% |
| 2015 FY | - USD | 85.84% |
| 2015 Q3 | -0.09 USD | 86.84% |
| 2015 Q1 | -0.09 USD | 96.04% |
| 2014 Q3 | -0.11 USD | 83.82% |
| 2014 FY | - USD | -42.38% |
| 2014 Q4 | -2.17 USD | -1872.73% |
| 2014 Q2 | -0.68 USD | 74.14% |
| 2014 Q1 | -2.63 USD | -179.79% |
| 2013 Q2 | -0.54 USD | 37.93% |
| 2013 Q4 | -0.94 USD | 40.51% |
| 2013 Q3 | -1.58 USD | -192.59% |
| 2013 FY | - USD | -33.45% |
| 2013 Q1 | -0.87 USD | -17.57% |
| 2012 Q1 | -0.55 USD | 11.29% |
| 2012 FY | - USD | 11.04% |
| 2012 Q4 | -0.74 USD | 21.28% |
| 2012 Q3 | -0.94 USD | -42.42% |
| 2012 Q2 | -0.66 USD | -20.0% |
| 2011 Q3 | -1.27 USD | -58.75% |
| 2011 Q1 | -0.57 USD | -62.86% |
| 2011 FY | - USD | -28.35% |
| 2011 Q2 | -0.80 USD | -40.35% |
| 2011 Q4 | -0.62 USD | 51.18% |
| 2010 Q1 | -0.41 USD | -17.14% |
| 2010 Q4 | -0.35 USD | 72.87% |
| 2010 Q3 | -1.29 USD | -152.94% |
| 2010 Q2 | -0.51 USD | -24.39% |
| 2010 FY | - USD | -55.83% |
| 2009 Q2 | -0.36 USD | 16.28% |
| 2009 Q4 | -0.35 USD | 22.22% |
| 2009 Q1 | -0.43 USD | 28.33% |
| 2009 FY | - USD | 0.61% |
| 2009 Q3 | -0.45 USD | -25.0% |
| 2008 Q3 | -0.46 USD | -109.09% |
| 2008 Q2 | -0.22 USD | 37.14% |
| 2008 FY | - USD | 15.46% |
| 2008 Q4 | -0.60 USD | -30.43% |
| 2008 Q1 | -0.35 USD | 27.08% |
| 2007 FY | - USD | 12.61% |
| 2007 Q2 | -0.43 USD | 8.51% |
| 2007 Q3 | -0.57 USD | -32.56% |
| 2007 Q4 | -0.48 USD | 15.79% |
| 2007 Q1 | -0.47 USD | 52.53% |
| 2006 Q4 | -0.99 USD | -41.43% |
| 2006 FY | - USD | -4705.19% |
| 2006 Q3 | -0.70 USD | 0.0% |
| 2006 Q2 | -0.70 USD | -118.75% |
| 2006 Q1 | -0.32 USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -0.60 USD | -16.667% |
| Ampio Pharmaceuticals, Inc. | -10.67 USD | 93.44% |
| Armata Pharmaceuticals, Inc. | -1.91 USD | 63.351% |
| Actinium Pharmaceuticals, Inc. | -1.83 USD | 61.749% |
| Azitra, Inc. | -54.76 USD | 98.722% |
| Can-Fite BioPharma Ltd. | -1.79 USD | 60.894% |
| Chromocell Therapeutics Corporation | -1.28 USD | 45.313% |
| Calidi Biotherapeutics, Inc. | -1.73 USD | 59.538% |
| CEL-SCI Corporation | -0.73 USD | 4.11% |
| iBio, Inc. | -6.50 USD | 89.231% |
| Lineage Cell Therapeutics, Inc. | -0.12 USD | -483.333% |
| MAIA Biotechnology, Inc. | -1.49 USD | 53.02% |
| Matinas BioPharma Holdings, Inc. | -5.28 USD | 86.742% |
| Navidea Biopharmaceuticals, Inc. | -0.59 USD | -18.644% |
| NovaBay Pharmaceuticals, Inc. | -138.65 USD | 99.495% |
| Oragenics, Inc. | -9.18 USD | 92.375% |
| BiomX Inc. | -5.10 USD | 86.275% |
| BiomX Inc. | -5.10 USD | 86.275% |
| Protalix BioTherapeutics, Inc. | 0.12 USD | 683.333% |
| Palatin Technologies, Inc. | -2.02 USD | 65.347% |
| Scorpius Holdings, Inc. | -347.20 USD | 99.798% |